NEW YORK – Using baseline blood samples, a group of researchers have identified a gene expression signature that may predict which patients with metastatic castration-resistant prostate cancer (CRPC) are most likely to respond to treatment with the antiandrogen agents abiraterone (Janssen's Zytiga) plus prednisone (AAP) or enzalutamide (Pfizer/Astellas' Xtandi).